Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778375 · ClinicalTrials.gov registry record · Phase 2
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00778375: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00778375 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778375, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older. The safety of this treatment will also be studied.
Interventions
- DRUG Decitabine
- DRUG Cytarabine
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00778375
The ClinicalTrials.gov registry entry for NCT00778375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Decitabine is the first listed.
NCT00778375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00778375 about?
NCT00778375 is a clinical study titled "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older. The safety of this treatment will also be studied.
What is the current status of trial NCT00778375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2008-10. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00778375?
The interventions under investigation include: Decitabine (DRUG), Cytarabine (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00778375?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.